Future treatments


  • Asciminib is a new drug developed for the treatment of CML by Novartis Pharma AG. It acts by inhibiting BCR-ABL1 and targeting the T315I It is effective on its own in the chronic phase of CML. For patients who do not achieve MMR, asciminib can added to imatinib, nilotinib and dasatinib to improve response.
  • Currently, the EMA have not approved asciminib. However, NICE is appraising asciminib for chronic phase CML treatment in patients previously treated with two or more TKIs. A recommendation guidance expected in July 2022 (https://www.nice.org.uk/guidance/indevelopment/gid-ta10691 )


  • Radotinib is a second generation TKI that has the same structure as nilotinib and effect against the BCR-ABL1mutation.
  • Radotinib was approved in Korea as front-line treatment for patients with CML in the chronic phase. This was based on a Korean clinical comparing radotinib and imatinib.
  • In the Korean trial, radotinib was superior to imatinib. However, the study needs repeating in European patients, given the well‑established higher response rates to TKIs in Asian populations.